Vancomycin: the need to suit serum concentrations in hemodialysis patients

Marengo, Lívia Luize; Del Fiol, Fernando de Sá; Oliveira, Sara de Jesus; Nakagawa, Celso; Croco, Eduardo Leite; Barberato-Filho, Silvio; Peçanha, Marcela Pellegrini; Silva, Douglas Felix da; Toledo, Maria Inês de.
Braz. j. infect. dis ; 14(2): 203-208, Mar.-Apr. 2010. ilus, tab
Artículo en Inglés | LILACS | ID: lil-548467

Documentos relacionados

  1. Vancomycin hemodialysis: Clearance differences between high-flux hemodialysis and on-line hemodiafiltration.
  2. Evaluation of weight-based vancomycin dosing for hospitalized hemodialysis patients.
  3. Vancomycin Dosing Regimen by Monte Carlo Simulation in Patients on Intermittent High-Efficiency Hemodialysis (HEHD).
  4. Microbiome perturbation by oral vancomycin reduces plasma concentration of two gut-derived uremic solutes, indoxyl sulfate and p-cresyl sulfate, in end-stage renal disease.
  5. Vancomycin levels are frequently subtherapeutic during continuous venovenous hemodialysis (CVVHD).
  6. Prospective validation of a model-informed precision dosing tool for vancomycin treatment in neonates.
  7. Optimization of therapeutic drug monitoring of vancomycin in patients with chronic hemodialysis
.
  8. Optimisation of vancomycin exposure in neonates based on the best level of evidence.
  9. The effect of neutropenia on the clinical pharmacokinetics of vancomycin in adults.
  10. Does oral vancomycin use necessitate therapeutic drug monitoring?